FDA's Biosimilar Inflection Point: Comparative Efficacy Studies Give Way to CMC as a US$40B Market Rewrites the Rules of Process Excellence
The global biosimilar market is worth roughly US$40B with potential compound growth near 20% over the next decade. The FDA is advancing two key policy shifts — relaxing comparative efficacy study (CES) requirements while strengthening process characterization and quality control (CMC) standards. The regulatory pivot raises the bar for the whole industry: first-to-launch share could exceed 30% with the top three taking 60–70%, making launch timing the revenue watershed and favoring CMC-strong players such as Henlius and WuXi Biologics.
The rules of the biosimilar game are being rewritten. According to sell-side research cited by CFI.cn on October 17, the global biosimilar market has reached roughly US$40B, with potential compound growth near 20% over the next decade. More consequentially, the US FDA is advancing two key policy adjustments: relaxing the requirement for comparative efficacy studies (CES) while strengthening standards for process characterization and quality control (CMC). For a segment long suppressed by the high cost and long timelines of clinical equivalence trials, this amounts to a shift in regulatory philosophy: the burden of proving "sufficiently similar" is moving from the bedside back to the manufacturing floor.
Why CMC becomes the new decisive factor
Under the traditional pathway, biosimilar developers often spent hundreds of millions of dollars on large comparative efficacy trials to prove no clinically meaningful differences from the originator. As regulators increasingly accept the logic that "the process is the product" — proving similarity through deep process characterization, quality-attribute comparison and analytical similarity — the weight of clinical studies falls and CMC capability becomes the core variable determining filing success and speed. The research note argues that this regulatory migration will directly raise industry barriers and widen the gap between leaders and laggards: process development, characterization and scale-up skill cannot be built overnight, and it is precisely the deepest moat of companies that have spent a decade or more in biologics CDMO and biosimilars.
Launch timing becomes the revenue watershed; first movers take most of the market
The note's competitive sketch is steep: the first approved biosimilar for a given molecule could capture over 30% market share, with the top three together reaching 60–70% — launch timing is the revenue watershed. Two external conditions are easing simultaneously: a wave of blockbuster biologic patent expiries is opening clear substitution windows, and US biosimilar price erosion versus originators is running at only about 25–30%, well below the 50%-plus discounts seen in early European markets, with clinical acceptance steadily rising. With volume, price and window aligning, biosimilars are no longer a thin-margin afterthought but a business that deserves re-rating.
Editorial view: three layers of implications for CXOs
This inflection transmits to the CXO industry on at least three levels. First, direct commercial opportunity: WuXi Biologics is one of the world's largest biosimilar CDMO providers, with its end-to-end platform supporting multiple globally approved biosimilars; Henlius, whose trastuzumab biosimilar HANQUYOU was among the first Chinese-developed biosimilars approved in Europe, and King-Friend Biochemical Pharmaceutical (Jianyou), a leading Chinese injectable exporter, are cited by the note as CMC-strong first-mover representatives. Second, repricing of capability: as the CES cost barrier falls and the CMC barrier rises, the outsourcing penetration of biosimilar development should rise systemically — more biotechs and emerging-market pharma will plug into CDMO process platforms rather than build full in-house stacks. Third, a timing dividend: weaker clinical requirements shorten filing cycles and raise the premium on capturing the "first / top-three" window — whoever locks process and files ahead of the patent cliff takes the fattest slice of cash flow. For Chinese CXOs, this is, after ADCs and peptides, another clear script of "regulatory change creating outsourcing demand."
FAQ
What is CES and why is the FDA relaxing it?
CES (Comparative Efficacy Study) is the large comparative clinical trial historically used to demonstrate equivalence between a biosimilar and its originator — costly and slow. The FDA is advancing policy adjustments to relax CES requirements and instead strengthen process characterization and quality control (CMC) standards, accelerating approvals through "analytical similarity + process evidence" and lowering development costs.
Why does CMC become the decisive factor for biosimilars?
As the center of similarity-proofing shifts from clinic to process, process development, quality characterization and scale-up robustness directly determine filing quality and speed. CMC capability cannot be built quickly, so incumbents with long accumulation gain a moat, industry barriers rise, and the gap with followers widens.
What does this mean for CXO companies?
Outsourcing penetration of biosimilar development should rise systemically: biosimilar CDMO leaders such as WuXi Biologics, and CMC-strong players like Henlius and Hippo Pharmaceuticals, hold first-mover advantages. With first-launch share above 30% and the top three at 60–70%, launch timing becomes the revenue watershed, and the speed of process lock-in becomes the core of competition.